ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$6.54
-0.46 (-6.64%)
▼
5d:
-6.78%
30d:
+15.66%
90d:
+18.82%
HOLD
LOW Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 13, 2026
23d
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ABEO is fairly valued with market pricing in 4.6% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: ABEO is fairly valued with market pricing in 4.6% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.56
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $6.54, which is considered slightly high relative to its 30-day fair value range of $5.62 to $6.85. From a valuation perspective, the stock is trading at a premium (Forward PE: 24.4) compared to its historical average (21.3). At these levels, the market is pricing in 4.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is in a strong uptrend. Immediate support is located at $6.22, while resistance sits at $7.36. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.71 (+181.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ABEO is in a strong uptrend. Immediate support is located at $6.22, while resistance sits at $7.36. Short-term momentum is weak, with the stock down 6.6% recently.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.71 (+181.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$5.62 -
$6.85
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.6%)
- BULLISH: Trading 181.6% below Wall St target ($19.71)
- NEUTRAL: Market pricing in 4.6% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -6.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.62 -
$6.85
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.22
Resistance Level
$7.36
Current Trend
Strong Uptrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.42
Wall Street Target
$19.71
(+181.6%)
Revenue Growth (YoY)
-100.0%
Profit Margin
454.9%
Valuation Premium vs History
+4.6% premium
PE vs Historical
24.4 vs 21.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$7.32
(+5%)
2-Year Target
$7.66
(+9%)
3-Year Target
$8.01
(+14%)
3-Yr Target (if PE normalizes)
(PE: 24→21)
PE COMPRESSION
$6.99
(0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 7.39 | Current EPS (TTM): $0.95
Bull Case
$3.86
(-45%)
Analyst growth -50.0%, PE expands to 8.1
Base Case
$3.51
(-50%)
Market implied -50.0%, PE stable at 7.4
Bear Case
$4.77
(-32%)
Severe decline -20.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 20, 2026 1:26 PM ET
Data refreshes hourly during market hours. Next update: 2:26 PM
Data refreshes hourly during market hours. Next update: 2:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Crombez
SELL
16284 shares
2026-02-02
Leila Alland
SELL
18065 shares
2026-02-02
Mark Alvino
SELL
2000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 61 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 51 HOLD |
